Eton Pharmaceuticals (ETON) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 159.5% versus a gain of 27.0%. Over five years, ETON leads with a +953.4% price change compared with +30.3% for TAK. Takeda Pharmaceutical is the larger company by market cap ($59.16 billion vs $1.56 billion), about 37.8 times the size.
On valuation, Eton Pharmaceuticals trades at a lower forward P/E (21.2x vs 34.9x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 1079.91%, while Eton Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | TAK |
|---|---|---|
| Share price | $54.75 | $18.52 |
| Market cap | $1.56B | $59.16B |
| 1-day change | -0.24% | +0.82% |
| YTD return | +224.54% | +17.83% |
| 1-year return | +159.48% | +27.04% |
| 5-year return | +953.36% | +30.28% |
| P/E ratio (TTM) | 136.88 | — |
| Forward P/E | 21.22 | 34.94 |
| EPS (TTM) | $0.40 | $-0.34 |
| Dividend yield | 0.00% | 1079.91% |
| Annual dividend | $0.00 | $200.00 |
| 52-week high | $66.37 | $19.10 |
| 52-week low | $14.27 | $12.99 |
| Distance from 52-week high | -17.51% | -3.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.68% | +18.57% |
| Average volume | 606.07K | 3.02M |
| Shares outstanding | 28.58M | 3.19B |
| Employees | 44 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 37.8 times larger than Eton Pharmaceuticals by market value ($59.16B vs $1.56B).
- ETON has outperformed TAK by 132.4 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1079.91% vs 0.00%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
ETON vs TAK FAQ
Which is bigger, Eton Pharmaceuticals or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.16B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or TAK?
ETON returned +159.48% over the past 12 months, compared with +27.04% for TAK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Eton Pharmaceuticals or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 1079.91%, while Eton Pharmaceuticals does not currently pay a regular dividend.
Are Eton Pharmaceuticals and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.